Neurocrine Biosciences, Inc. (NBIX) Market Cap & Valuation Ratios
Neurocrine Biosciences, Inc. (NBIX) has a market cap of $14.5B, a trailing P/E of 20.9 and a price-to-sales ratio of 4.3, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NBIXNeurocrine Biosciences, Inc.Follow NBIX — free
—
Price chart with a free account
- Market cap
- 14.5B
- P/E TTM
- 20.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Peers
drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| NBIX | 15 | 20.9 | 4.2 | 16.8 | 6.0% | +34% | 24% | 21% |
| ZTS | 33 | 13.3 | 4.3 | 10.2 | 6.9% | +1% | 37% | 29% |
| UTHR | 25 | 21.0 | 7.1 | 15.1 | 4.3% | +2% | 44% | 23% |
| VTRS | 21 | — | 2.2 | 12.2 | 9.5% | +4% | -0.6% | -0.3% |
| ELAN | 11 | — | 2.9 | 27.8 | 3.4% | +12% | -3% | -2% |
| ALKS | 7.3 | 114.8 | 4.9 | 45.6 | 3.0% | +11% | 7% | 3% |
| LNTH | 6.5 | 24.2 | 4.2 | 16.6 | 6.0% | +2% | 19% | 20% |
| AMRX | 6.5 | 41.6 | 2.9 | 14.0 | 1.3% | +9% | 15% | 17% |
| HIMS | 6.5 | — | 2.7 | — | 1.0% | +28% | -6% | -21% |
| KNSA | 6.0 | 78.3 | 6.5 | 53.5 | 3.1% | +59% | 12% | 18% |
| INDV | 4.1 | 12.4 | 3.3 | 10.1 | -2.7% | +13% | 32% | 667% |
| Median of these 10 | 24.2 | 3.7 | 15.1 | 3.2% | +10% | 13% | 18% |
P/E 20.9 vs. a peer median of 24.2; EV/Sales 4.2 vs. 3.7. NBIX's own P/E sits at the 8th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesVTRS and ELAN and HIMS have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Neurocrine Biosciences, Inc. — questions
- What is Neurocrine Biosciences, Inc.'s market cap?
- $14.5B.
- What is Neurocrine Biosciences, Inc.'s P/E ratio?
- 20.9 on trailing twelve-month earnings to 2026-06-30.
- What is Neurocrine Biosciences, Inc.'s price-to-sales ratio?
- 4.3.
Every figure on this page comes from Neurocrine Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.